000276329 001__ 276329
000276329 005__ 20240229154959.0
000276329 0247_ $$2doi$$a10.1016/j.clnu.2023.05.009
000276329 0247_ $$2pmid$$apmid:37244755
000276329 0247_ $$2ISSN$$a0261-5614
000276329 0247_ $$2ISSN$$a1532-1983
000276329 0247_ $$2altmetric$$aaltmetric:148450135
000276329 037__ $$aDKFZ-2023-01059
000276329 041__ $$aEnglish
000276329 082__ $$a610
000276329 1001_ $$0P:(DE-He78)35a941418cdcc6c595b7a8a19e355599$$aGwenzi, Tafirenyika$$b0$$eFirst author$$udkfz
000276329 245__ $$aEffects of vitamin D supplementation on inflammatory response in patients with cancer and precancerous lesions: Systematic review and meta-analysis of randomized trials.
000276329 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2023
000276329 3367_ $$2DRIVER$$aarticle
000276329 3367_ $$2DataCite$$aOutput Types/Journal article
000276329 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687349125_6281
000276329 3367_ $$2BibTeX$$aARTICLE
000276329 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276329 3367_ $$00$$2EndNote$$aJournal Article
000276329 500__ $$a2023 Jul;42(7):1142-1150 / #EA:C120#LA:C120#LA:C070#
000276329 520__ $$aInflammation plays a key role in tumor development and progression. Vitamin D has potential tumor suppressing effects through modulation of inflammatory processes. The aim of this systematic review and meta-analysis of randomized controlled trials (RCTs) was to summarize and evaluate the effects of vitamin D3 supplementation (VID3S) on serum inflammatory biomarkers among patients with cancer or pre-cancerous lesions.We searched PubMed, Web of Science and Cochrane databases until November 2022. The effects of VID3S were estimated from pooled standardized mean differences (SMDs) with their 95% confidence intervals (CIs) for inflammatory biomarker follow-up levels between intervention and control groups.Meta-analysis of eight RCTs (total of 592 patients with cancer or pre-cancerous conditions) showed that VID3S significantly lowered levels of serum tumor necrosis factor (TNF)-α (SMD [95%CI]: -1.65 [-3.07; -0.24]). VID3S also resulted in statistically non-significantly lower serum levels of interleukin (IL)-6 (SMD [95%CI]: -0.83, [-1.78; 0.13]) and C-reactive protein (CRP) (SMD [95%CI]: -0.09, [-0.35; 0.16]), whereas IL-10 levels were unaltered (SMD [95%CI]: -0.00, [-0.50; 0.49]).Our study shows evidence of a significant reduction of TNF-α levels by VID3S for patients with cancer or precancerous lesions. Patients with cancer or precancerous lesions may benefit from personalized VID3S in suppressing tumour-promoting inflammatory response.CRD42022295694.
000276329 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000276329 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276329 650_7 $$2Other$$aBiomarker
000276329 650_7 $$2Other$$aCancer
000276329 650_7 $$2Other$$aInflammation
000276329 650_7 $$2Other$$aPrecancer
000276329 650_7 $$2Other$$aVitamin D3 supplement
000276329 7001_ $$0P:(DE-He78)e71d98af5fac4f81eb58e74b7b3095c2$$aZhu, Anna$$b1$$udkfz
000276329 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b2$$udkfz
000276329 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b3$$udkfz
000276329 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b4$$udkfz
000276329 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000276329 773__ $$0PERI:(DE-600)2009052-3$$a10.1016/j.clnu.2023.05.009$$gp. S0261561423001516$$n7$$p1142-1150$$tClinical nutrition$$v42$$x0261-5614$$y2023
000276329 909CO $$ooai:inrepo02.dkfz.de:276329$$pVDB
000276329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)35a941418cdcc6c595b7a8a19e355599$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000276329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e71d98af5fac4f81eb58e74b7b3095c2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000276329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000276329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000276329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000276329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000276329 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000276329 9141_ $$y2023
000276329 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-12
000276329 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-12
000276329 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-28$$wger
000276329 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN NUTR : 2022$$d2023-08-28
000276329 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-28
000276329 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-28
000276329 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-28
000276329 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-28
000276329 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-28
000276329 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN NUTR : 2022$$d2023-08-28
000276329 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000276329 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000276329 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000276329 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000276329 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000276329 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000276329 980__ $$ajournal
000276329 980__ $$aVDB
000276329 980__ $$aI:(DE-He78)C120-20160331
000276329 980__ $$aI:(DE-He78)C070-20160331
000276329 980__ $$aI:(DE-He78)HD01-20160331
000276329 980__ $$aUNRESTRICTED